Relapses, treatments and new drugs

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 1, 2012, Pages 49-60

  Mounier, Nicolas ^a,b   Gisselbrecht, Christian ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

diffuse large B cell lymphoma; monoclonal antibody; salvage chemotherapy; small molecule inhibitors

Indexed keywords

ANTIBIOTIC AGENT; BLINATUMOMAB; BORTEZOMIB; CALICHEAMYCIN; CARBOPLATIN; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACETUZUMAB; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; INOTUZUMAB OZOGAMICIN; LEXATUMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MAPATUMUMAB; OBINUTUZUMAB; OFATUMUMAB; OXALIPLATIN; PCI 32765; PLACEBO; PLATINUM; PREDNISONE; RITUXIMAB; SAR 349; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE;

ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC DISEASE; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOGLOBULIN DEFICIENCY; INFECTION; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEDIASTINUM DISEASE; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROTEIN KINASE INHIBITORS; RECURRENCE; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 84858315011     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.01.002     Document Type: Review

References (37)

1. N. Murawski, and M. Pfreundschuh New drugs for aggressive B-cell and T-cell lymphomas Lancet Oncol 11 2010 1074 1085
2. C.B. Reeder, and S.M. Ansell Novel therapeutic agents for B-cell lymphoma: developing rational combinations Blood 117 2011 1453 1462
3. B. Coiffier, C. Thieblemont, and E. Van Den Neste Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 2010 2040 2045
4. T. Philip, C. Guglielmi, and A. Hagenbeek Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma N Engl J Med 333 1995 1540 1545
5. E. Vellenga, W.L. van Putten, and M.B. van 't Veer Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood 111 2008 537 543
6. C. Gisselbrecht, B. Glass, and N. Mounier Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 28 2010 4184 4190
7. C. Gisselbrecht, B. Glass, and G. Laurent Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis J Clin Oncol 29 2011 [abstract 8004]
8. I.F. Khouri, R.M. Saliba, and C. Hosing Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas J Clin Oncol 23 2005 2240 2247 (Pubitemid 46218716)
9. S.M. Horwitz, R.S. Negrin, and K.G. Blume Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-hodgkin lymphoma Blood 103 2004 777 783 (Pubitemid 38129532)
10. S. Swerdlow, E. Campo, and N.L. Harris World health organisation classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2008 World Health Organisation Geneva [pp. 168-170]
11. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511 (Pubitemid 30082188)
12. E. Campo, S.H. Swerdlow, and N.L. Harris The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 117 2011 5019 5032
13. C. Thieblemont, J. Briere, and N. Mounier The germinal center (GCB)/activated B-cell (ABC) subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The bio-CORAL study J Clin Oncol 2011
14. C.P. Hans, D.D. Weisenburger, and T.C. Greiner Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 2004 275 282 (Pubitemid 38029949)
15. A. Advani, B. Coiffier, and M.S. Czuczman Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-hodgkin's lymphoma: results of a phase I study J Clin Oncol 28 2010 2085 2093
16. B. Coiffier, V. Ribrag, and J. Dupuis Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell non-hodgkin's lymphoma. 11th international conference on malignant lymphoma 15-18 June 2011, Lugano (Switzerland) Ann Oncol 22 2011 [abstr 070]
17. G. Cartron, C. Thieblemont, and P. Solal-Celigny Results from a phase II study of RO5072759 (GA101) monotherapy in relapsed/refractory aggressive non-hodgkin's lymphoma. 11th international conference on malignant lymphoma 15-18 June 2011, Lugano (Switzerland) Ann Oncol 22 2011 [abstr 144]
18. M. Goebeler, A. Viardot, and R. Noppeney Blinatumomab (CD3/CD19 BITE- antibody) results in a high response rate in patients with relapsed non hodgkin lymphoma including MCL and DLBCL. 11th international conference on malignant lymphoma 15-18 June 2011, Lugano (Switzerland) Ann Oncol 22 2011 [abstr 068]
19. R. Advani, A. Forero-Torres, and R.R. Furman Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-hodgkin's lymphoma J Clin Oncol 27 2009 4371 4377
20. L.M. Fayad, S. Ansell, and R. Advani A phase 2b trial comparing dacetuzumab + R-ICE vs. placebo + R-ICE in patients with relapsed diffuse large B-cell lymphoma. 11th international conference on malignant lymphoma 15-18 June 2011, Lugano (Switzerland) Ann Oncol 22 2011 [abstr 145]
21. M.A. Shipp, K.N. Ross, and P. Tamayo Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8 2002 68 74 (Pubitemid 34101731)
22. M.J. Robertson, B.S. Kahl, and J.M. Vose Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 2007 1741 1746 (Pubitemid 46797955)
23. J. Hainsworth, E. Arrowsmith, and M. Mccleod Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate and high-risk diffuse large b-cell lymphoma - preliminary analysis.11th international conference on malignant lymphoma 15-18 June 2011, Lugano (Switzerland) Ann Oncol 22 2011 [abstr 74]
24. J.W. Friedberg, J. Sharman, and J. Sweetenham Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2010 2578 2585
25. R.E. Davis, V.N. Ngo, and G. Lenz Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 2010 88 92
26. R. Advani, J.P. Sharman, and S. Smith The btk inhibitor pci-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I study. 11th international conference on malignant lymphoma 15-18 June 2011, Lugano (Switzerland) Ann Oncol 22 2011 [abstr 144]
27. V. Ribrag, C. Gisselbrecht, and C. Haioun Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the french adult lymphoma study group (GELA) Cancer 115 2009 4540 4546
28. J. Ruan, P. Martin, and R.R. Furman Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol 29 2011 690 697
29. K. Dunleavy, S. Pittaluga, and M.S. Czuczman Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 113 2009 6069 6076
30. O.A. O'Connor, A.K. Stewart, and M. Vallone A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin Cancer Res 15 2009 7085 7091
31. P.H. Wiernik, I.S. Lossos, and J.M. Tuscano Lenalidomide monotherapy in relapsed or refractory aggressive non-hodgkin's lymphoma J Clin Oncol 26 2008 4952 4957
32. T.E. Witzig, J.M. Vose, and P.L. Zinzani An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-hodgkin's lymphoma Ann Oncol 22 2011 1622 1627
33. F.J. Hernandez-Ilizaliturri, G. Deeb, and P.L. Zinzani Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype Cancer 2011
34. G.S. Nowakowski, B. Laplant, and T.M. Habermann Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study Leukemia 2011
35. S.M. Smith, K. van Besien, and T. Karrison Temsirolimus has activity in non-mantle cell non-hodgkin's lymphoma subtypes: the university of Chicago phase II consortium J Clin Oncol 28 2010 4740 4746
36. M. Crump, B. Coiffier, and E.D. Jacobsen Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Ann Oncol 19 2008 964 969 (Pubitemid 351627315)
37. G. Lenz, G.W. Wright, and N.C. Emre Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci U S A 105 2008 13520 13525